These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27332992)

  • 1. Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease.
    Blinc A; Kozak M; Šabovič M; Božič Mijovski M; Stegnar M; Poredoš P; Kravos A; Barbič-Žagar B; Stare J; Pohar Perme M
    Int Angiol; 2017 Jun; 36(3):216-227. PubMed ID: 27332992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of ischemic events in patients with peripheral arterial disease design, baseline characteristics and 2-year results an observational study.
    Blinc A; Kozak M; Sabovic M; Božic M; Stegnar M; Poredoš P; Kravos A; Barbic-Žagar B; Pohar Perme M; Stare J;
    Int Angiol; 2011 Dec; 30(6):555-66. PubMed ID: 22233617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
    Sigvant B; Kragsterman B; Falkenberg M; Hasvold P; Johansson S; Thuresson M; Nordanstig J
    J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort.
    Zeymer U; Parhofer KG; Pittrow D; Binz C; Schwertfeger M; Limbourg T; Röther J
    Clin Res Cardiol; 2009 Apr; 98(4):249-56. PubMed ID: 19221687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and smoking are more important for prognosis of patients with peripheral arterial disease than some genetic polymorphisms.
    Boc V; Božic Mijovski M; Pohar Perme M; Blinc A
    Vasa; 2019 May; 48(3):229-235. PubMed ID: 30526437
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
    Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP
    Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease.
    Lee JH; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    J Vasc Surg; 2016 Mar; 63(3):756-63. PubMed ID: 26603545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization.
    Thiney M; Della Schiava N; Ecochard R; Feugier P; Lermusiaux P; Millon A; Long A
    Ann Vasc Surg; 2018 Oct; 52():138-146. PubMed ID: 29777848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymptomatic cerebral infarction is a predictor of long-term survival and vascular or limb events in peripheral arterial disease.
    Kumakura H; Kanai H; Matsuo Y; Iwasaki T; Ichikawa S
    Eur Heart J Qual Care Clin Outcomes; 2019 Jan; 5(1):43-50. PubMed ID: 29931172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains.
    Subherwal S; Patel MR; Kober L; Peterson ED; Jones WS; Gislason GH; Berger J; Torp-Pedersen C; Fosbol EL
    Circulation; 2012 Sep; 126(11):1345-54. PubMed ID: 22874581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent Impact of Peripheral Artery Disease on Percutaneous Coronary Intervention.
    Perl L; Bental T; Vaknin-Assa H; Assali A; Codner P; Talmor-Barkan Y; Greenberg G; Samara A; Witberg G; Orvin K; Kornowski R
    J Am Heart Assoc; 2020 Dec; 9(24):e017655. PubMed ID: 33283578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.
    Inohara T; Pieper K; Wojdyla DM; Patel MR; Jones WS; Tricoci P; Mahaffey KW; James SK; Alexander JH; Lopes RD; Wallentin L; Ohman EM; Roe MT; Vemulapalli S
    Am Heart J; 2018 Jul; 201():25-32. PubMed ID: 29910052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
    Poredos P; Jezovnik MK
    Vasa; 2013 Mar; 42(2):88-95. PubMed ID: 23485835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?
    Poredos P; Jezovnik MK
    Int J Mol Sci; 2015 Jun; 16(7):14477-89. PubMed ID: 26121301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease.
    Giugliano G; Di Serafino L; Perrino C; Schiano V; Laurenzano E; Cassese S; De Laurentis M; Schiattarella GG; Brevetti L; Sannino A; Gargiulo G; Franzone A; Indolfi C; Piscione F; Trimarco B; Esposito G
    Int J Cardiol; 2013 Sep; 167(6):2566-71. PubMed ID: 22790191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral artery disease patients may benefit more from aggressive secondary prevention than aneurysm patients to improve survival.
    Ultee KHJ; Hoeks SE; Gonçalves FB; Boersma E; Stolker RJ; Verhagen HJM; Rouwet EV
    Atherosclerosis; 2016 Sep; 252():147-152. PubMed ID: 27544931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease.
    Urbonaviciene G; Frystyk J; Flyvbjerg A; Henneberg EW; Lindholt JS
    Atherosclerosis; 2010 Jun; 210(2):619-24. PubMed ID: 20096841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.